Global & Regional Health Technology Assessment最新文献

筛选
英文 中文
Il burden economico e sociale della porpora trombotica trombocitopenica congenita (cTTP) in Italia. 意大利先天性血栓性血小板减少性紫癜 (cTTP) 的经济和社会负担。
IF 0.4
Global & Regional Health Technology Assessment Pub Date : 2024-10-28 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.3147
Filippo Rumi, Michele Basile, Eugenio Di Brino, Agostino Fortunato, Debora Antonini
{"title":"Il burden economico e sociale della porpora trombotica trombocitopenica congenita (cTTP) in Italia.","authors":"Filippo Rumi, Michele Basile, Eugenio Di Brino, Agostino Fortunato, Debora Antonini","doi":"10.33393/grhta.2024.3147","DOIUrl":"https://doi.org/10.33393/grhta.2024.3147","url":null,"abstract":"","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11519643/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug utilization and medication adherence for the treatment of psoriatic arthritis: an Italian study. 治疗银屑病关节炎的药物使用和用药依从性:一项意大利研究。
IF 0.4
Global & Regional Health Technology Assessment Pub Date : 2024-10-09 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.3204
Fiorenzo Santoleri, Paolo Abrate, Laura Pestrin, Enrico Pasut, Germana Modesti, Felice Musicco, Chiara Fulgenzio, Eva Zuzolo, Gabriella Pieri, Martina Roperti, Pietro Gazzola, Marco Gambera, Isabella Martignoni, Valentina Montresor, Francesca Guarino, Laura Grossi, Letizia Di Fabio, Cristina Roberti, Concetta Spoltore, Gabriella Tinari, Stefania De Rosa, Romina Giannini, Roberto Langella, Grazia Mingolla, Mariantonietta Piccoli, Alberto Costantini
{"title":"Drug utilization and medication adherence for the treatment of psoriatic arthritis: an Italian study.","authors":"Fiorenzo Santoleri, Paolo Abrate, Laura Pestrin, Enrico Pasut, Germana Modesti, Felice Musicco, Chiara Fulgenzio, Eva Zuzolo, Gabriella Pieri, Martina Roperti, Pietro Gazzola, Marco Gambera, Isabella Martignoni, Valentina Montresor, Francesca Guarino, Laura Grossi, Letizia Di Fabio, Cristina Roberti, Concetta Spoltore, Gabriella Tinari, Stefania De Rosa, Romina Giannini, Roberto Langella, Grazia Mingolla, Mariantonietta Piccoli, Alberto Costantini","doi":"10.33393/grhta.2024.3204","DOIUrl":"https://doi.org/10.33393/grhta.2024.3204","url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to evaluate the persistence, treatment adherence and drug cost associated with biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the management of psoriatic arthritis (PsA) in Italy, with a focus on biosimilar drugs.</p><p><strong>Methods: </strong>This was a retrospective observational study involving eight hospital pharmacies, between January 2017 and December 2020, on naïve patients with at least one b/tsDMARD dispensation indicated for PsA. Patients were followed up for 12 months and persistence and adherence were evaluated by proportion of days covered (PDC). The originator and biosimilar for adalimumab and etanercept were compared. Furthermore, the real annual cost per patient based on adherence to therapy was calculated.</p><p><strong>Results: </strong>Patients initiating b/tsDMARDs for PsA had a mean persistence of 263 days and 48.6% remained persistent for 1 year. Adherent patients (PDC ≥ 0.8) were 47.6% for the overall population. Similar persistence and adherence were observed between patients treated with the adalimumab originator and its biosimilar, while patients treated with the etanercept originator showed lower persistence and adherence compared to those treated with its biosimilar (mean persistence: 222 vs. 267 days, patient persistent at 1 year: 29.4% vs. 51.5%, mean PDC: 0.53 vs. 0.70, adherent patients: 23.5% vs. 51.5%). The average annual drug cost ranged from €8,724 (etanercept) to €14,783 (ustekinumab), with an annual saving of more than €2,500 by using biosimilars.</p><p><strong>Conclusion: </strong>Poor adherence to medications contributes to suboptimal clinical outcomes. The comparison between biosimilar and originator offers further evidence in support of the biosimilar to optimizing resources in healthcare.</p>","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467683/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142462935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analisi di impatto sul budget sanitario italiano di roxadustat per il trattamento dell’anemia da malattia renale cronica. 罗沙司他治疗慢性肾病引起的贫血症对意大利医疗预算的影响分析。
IF 0.4
Global & Regional Health Technology Assessment Pub Date : 2024-09-10 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.3062
Chiara Bini, Andrea Marcellusi, Paolo Di Rienzo, Lucia Del Vecchio
{"title":"Analisi di impatto sul budget sanitario italiano di roxadustat per il trattamento dell’anemia da malattia renale cronica.","authors":"Chiara Bini, Andrea Marcellusi, Paolo Di Rienzo, Lucia Del Vecchio","doi":"10.33393/grhta.2024.3062","DOIUrl":"https://doi.org/10.33393/grhta.2024.3062","url":null,"abstract":"","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11393551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142284190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The efficacy of dalbavancin and impact on hospitalization and treatment costs in patients with ABSSSI. 达巴万星的疗效及其对 ABSSSI 患者住院时间和治疗费用的影响。
IF 0.4
Global & Regional Health Technology Assessment Pub Date : 2024-07-29 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.3045
Sergio Carbonara
{"title":"The efficacy of dalbavancin and impact on hospitalization and treatment costs in patients with ABSSSI.","authors":"Sergio Carbonara","doi":"10.33393/grhta.2024.3045","DOIUrl":"10.33393/grhta.2024.3045","url":null,"abstract":"<p><p>Acute bacterial skin and skin structure infections (ABSSSIs) represent a common and costly healthcare burden, accounting for millions of annual infections and billions of dollars in healthcare expenditures. Dalbavancin is a long-acting glycopeptide antibiotic that has demonstrated efficacy and safety in the treatment of ABSSSIs. This review article will examine the efficacy of dalbavancin and focus on its impact on the hospital length of stay and costs associated with management of these infections.</p>","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292618/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Usefulness of dalbavancin in early discharge and nonhospitalization. It's time to throw your heart over the obstacle? 达巴万星在早期出院和非住院治疗中的作用。是时候把心扔到障碍物上了吗?
IF 0.4
Global & Regional Health Technology Assessment Pub Date : 2024-07-29 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.3071
Massimo Crapis, Sergio Venturini, Astrid Callegari, Giovanni Del Fabro, Igor Bramuzzo, Laura De Santi, Elisa Pontoni, Maurizio Tonizzo, Barbara Basso
{"title":"Usefulness of dalbavancin in early discharge and nonhospitalization. It's time to throw your heart over the obstacle?","authors":"Massimo Crapis, Sergio Venturini, Astrid Callegari, Giovanni Del Fabro, Igor Bramuzzo, Laura De Santi, Elisa Pontoni, Maurizio Tonizzo, Barbara Basso","doi":"10.33393/grhta.2024.3071","DOIUrl":"10.33393/grhta.2024.3071","url":null,"abstract":"<p><strong>Introduction: </strong>Dalbavancin is a semisynthetic lipoglycopeptide long-acting antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). Its features can be useful in the current healthcare scenario characterized by the shortage of available hospital beds.</p><p><strong>Materials methods and results: </strong>We implemented several actions in order to optimize the use of dalbavancin allowing an improvement strategy both from the healthcare system and the patient's perspective in two hospital settings. In the Emergency Department we hospitalized only patients who met the clinical criteria and not the logistic criteria (i.e., the need for antibiotic therapy infusion). During the years 2017-2023, this strategy was applied in 40 cases, thus avoiding 40 hospitalizations for a total saving of 280 days of hospitalization.In the Internal Medicine ward and surgery department when there was no longer any need for hospitalization, we discharged the patient as early as possible. During the years 2017-2023, this strategy was applied in 189 cases, saving at least 1,134 days of hospitalization. The outcome of the treated patients was favorable in 228 out of 229 patients (99.5%).</p><p><strong>Conclusions: </strong>Our experience using dalbavancin in ABSSSI has been very satisfactory overall. The efficacy was close to 100%. Minor adverse events of slight severity occurred rarely. At the same time, this strategy allowed a more efficient allocation of hospital beds. Dalbavancin presents an ideal pharmacodynamic/pharmacokinetic profile for the management of ABSSSI especially in settings where shortage of hospital beds is critical.</p>","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease network. 从临床、组织和药物经济学角度看达巴万星与传染病网络中的标准护理。
IF 0.4
Global & Regional Health Technology Assessment Pub Date : 2024-07-29 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.3094
Daniela Segala, Marco Barbieri, Mariachiara Di Nuzzo, Melissa Benazzi, Aurora Bonazza, Letizia Romanini, Brunella Quarta, Kristian Scolz, Anna Marra, Diana Campioni, Rosario Cultrera
{"title":"Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease network.","authors":"Daniela Segala, Marco Barbieri, Mariachiara Di Nuzzo, Melissa Benazzi, Aurora Bonazza, Letizia Romanini, Brunella Quarta, Kristian Scolz, Anna Marra, Diana Campioni, Rosario Cultrera","doi":"10.33393/grhta.2024.3094","DOIUrl":"10.33393/grhta.2024.3094","url":null,"abstract":"<p><strong>Introduction: </strong>The therapeutic approach to the patient with acute bacterial skin and skin structure infection (ABSSSI) and complicated infections often involves the early transition from intravenous to oral therapy (early switch) or early discharge. Our study aimed to evaluate sustainable and innovative care models that can be transferred to community healthcare and the economic impact of dalbavancin therapy vs Standard of Care (SoC) therapy for the treatment of ABSSSI and other Gram-positive infections including those by multidrug-resistant organisms. We also described the organization of an infectious disease network that allows optimizing the treatment of ABSSSI and other complex infections with dalbavancin.</p><p><strong>Materials and methods: </strong>We retrospectively studied all patients treated with dalbavancin in the University Hospital \"S. Anna\" of Ferrara, Italy, between November 2016 and December 2022. The clinical information of each patient was collected from the hospital's SAP database and used to evaluate the impact of dalbavancin in early discharge with reduction of length of stay promoting dehospitalization and in improving adherence to antibiotic therapy.</p><p><strong>Results: </strong>A total of 287 patients (165 males and 122 females) were included in the study of which 62 were treated with dalbavancin. In 13/62 patients dalbavancin was administered in a single dose at the completion of therapy to facilitate early discharge. Assuming a 12-day hospitalization required for the treatment of ABSSSI or to complete the treatment of osteomyelitis or spondilodiscitis, the treatment with dalbavancin results in a cost reduction of more than €3,200 per single patient compared to SoC (dancomycin, linezolid or vancomycin).</p><p><strong>Conclusions: </strong>Dalbavancin has proven to be a valid therapeutic aid in the organization of a territorial infectious disease network given its prolonged action, which allows the dehospitalization with management of even patients with complex infections in outpatient parenteral antimicrobial therapy.</p>","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141891550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Place in therapy of dalbavancin to treat Gram-positive infections in antimicrobial resistance era: an overview. 抗菌药耐药性时代达巴万星治疗革兰氏阳性感染的地位:综述。
IF 0.4
Global & Regional Health Technology Assessment Pub Date : 2024-07-29 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.3108
Rosario Cultrera
{"title":"Place in therapy of dalbavancin to treat Gram-positive infections in antimicrobial resistance era: an overview.","authors":"Rosario Cultrera","doi":"10.33393/grhta.2024.3108","DOIUrl":"10.33393/grhta.2024.3108","url":null,"abstract":"","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292619/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Models of care and relevance of territorial management in assisting persons with epilepsy. 帮助癫痫患者的护理模式和属地管理的相关性。
IF 0.4
Global & Regional Health Technology Assessment Pub Date : 2024-07-22 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.2889
Oriano Mecarelli
{"title":"Models of care and relevance of territorial management in assisting persons with epilepsy.","authors":"Oriano Mecarelli","doi":"10.33393/grhta.2024.2889","DOIUrl":"10.33393/grhta.2024.2889","url":null,"abstract":"<p><p>Epilepsy is a widespread social disease that affects people of all ages and often involves both diagnostic and therapeutic difficulties. Beyond seizure control, it is necessary to ensure people with epilepsy a good quality of life and respect for human rights, seeking to increase self-management capacity and break down stigma. People with epilepsy should have privileged access to specialized epilepsy centers, where multidisciplinary care is possible. These centers, organized by different levels of complexity, should be uniformly distributed throughout the country and networked together. The scientific community and health care organizations must therefore design all necessary strategies so that knowledge about epilepsy improves among the general population and the most effective pathways of care are effectively implemented.</p>","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11270230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of the hospital pharmacist to guarantee access and continuity of care for the management of epilepsy. 医院药剂师在保证癫痫治疗的可及性和连续性方面的作用。
IF 0.4
Global & Regional Health Technology Assessment Pub Date : 2024-07-22 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.2970
Marcello Pani
{"title":"The role of the hospital pharmacist to guarantee access and continuity of care for the management of epilepsy.","authors":"Marcello Pani","doi":"10.33393/grhta.2024.2970","DOIUrl":"10.33393/grhta.2024.2970","url":null,"abstract":"<p><p>In this article the pivotal role of hospital pharmacists in the multidisciplinary management of epilepsy is discussed. Hospital pharmacists are members of national and local ethics committees, oversee clinical trials, and ensure adherence to regulations for patient access to novel therapeutic treatments. They actively contribute to regulatory processes and the definition of prescribing centers. In the post-launch phase, hospital pharmacists are a key member in the multidisciplinary team, they are involved in decisions relating to the local introduction of drugs, in the management of the drug within the hospital structure and with the direct distribution, and to ensure proper and timely treatment. The pharmacovigilance network, including hospital and community pharmacists, monitors and prevents adverse effects related to epilepsy medications and enhances a collaborative approach with specialists to promote prescription appropriateness, targeting therapy for better patient outcomes. Finally, the potential benefits of deprescribing are briefly discussed, underscoring the importance of a multidisciplinary approach involving doctors and clinical pharmacists to gather comprehensive data and enhance patient care in epilepsy management.</p>","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11270225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hospital pharmacists and their role in the management of epilepsy. 医院药剂师及其在癫痫管理中的作用。
IF 0.4
Global & Regional Health Technology Assessment Pub Date : 2024-07-22 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.2890
Marcello Pani
{"title":"Hospital pharmacists and their role in the management of epilepsy.","authors":"Marcello Pani","doi":"10.33393/grhta.2024.2890","DOIUrl":"https://doi.org/10.33393/grhta.2024.2890","url":null,"abstract":"","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11270224/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信